Valproic acid attenuates proteinuria and kidney injury

Journal of the American Society of Nephrology

Volumn 22, Issue 10, 2011, Pages 1863-1875

  Van Beneden, Katrien ^a   Geers, Caroline ^b   Pauwels, Marina ^a   Mannaerts, Inge ^a   Verbeelen, Dierik ^a   Van Grunsven, Leo A ^a   Van Den Branden, Christiane ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DOXORUBICIN; HISTONE DEACETYLASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE CONTROL; GLOMERULOSCLEROSIS; KIDNEY INJURY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA;

EID: 80053519863     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111196     Document Type: Article

References (51)

1. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54: 687-697, 1998 (Pubitemid 28397387)
2. Chen A, Sheu LF, Ho YS, Lin YF, Chou WY, Chou TC, Lee WH: Experimental focal segmental glomerulosclerosis in mice. Nephron 78: 440-452, 1998 (Pubitemid 28154166)
3. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 29: 502-510, 1986 (Pubitemid 16129061)
4. Wang Y, Wang YP, Tay YC, Harris DC: Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int 58: 1797-1804, 2000
5. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, Krofft RD, Logar CM, Marshall CB, Ohse T, Shankland SJ: Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 296: F213-F229, 2009
6. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A: Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51: 603-614, 2010
7. Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867, 1999 (Pubitemid 29109602)
8. Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, Hellemans K, De Bleser P, Gelman I, Ramadori G, Geerts A: Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 37: 788-796, 2002 (Pubitemid 35404218)
9. Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A: Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg 64: 239-246, 2001 (Pubitemid 32953886)
10. Bush EW, McKinsey TA: Protein acetylation in the cardiorenal axis: The promise of histone deacetylase inhibitors. Circ Res 106: 272-284, 2010
11. Pang M, Zhuang S: Histone deacetylase: A potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 335: 266-272, 2010
12. Marumo T, Hishikawa K, Yoshikawa M, Hirahashi J, Kawachi S, Fujita T: Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298: F133-F141, 2010
13. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297: F996-F1005, 2009
14. Cao Y, Semanchik N, Lee SH, Somlo S, Barbano PE, Coifman R, Sun Z: Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci U S A 106: 21819-21824, 2009
15. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB: Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 297: F729-F739, 2009
16. Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D, Klussmann S, Tikoo K, Anders HJ: Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrol Dial Transplant 25: 1811-1817, 2010
17. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS: Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111: 539-552, 2003 (Pubitemid 36228011)
18. Yoshikawa M, Hishikawa K, Marumo T, Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007 (Pubitemid 46053422)
19. Freidkin I, Herman M, Tobar A, Chagnac A, Ori Y, Korzets A, Gafter U: Effects of histone deacetylase inhibitors on rat mesangial cells. Am J Physiol Renal Physiol 298: F426-F434, 2010
20. De Groh ED, Swanhart LM, Cosentino CC, Jackson RL, Dai W, Kitchens CA, Day BW, Smithgall TE, Hukriede NA: Inhibition of histone deacetylase expands the renal progenitor cell population. J Am Soc Nephrol 21: 794-802, 2010
21. Imai N, Hishikawa K, Marumo T, Hirahashi J, Inowa T, Matsuzaki Y, Okano H, Kitamura T, Salant D, Fujita T: Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury. Stem Cells 25: 2469-2475, 2007 (Pubitemid 47582739)
22. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr.: Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 2005 (Pubitemid 40946533)
23. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001 (Pubitemid 34062289)
24. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589, 2008 (Pubitemid 351184977)
25. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002
26. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009
27. Zacharias N, Sailhamer EA, Li Y, Liu B, Butt MU, Shuja F, Velmahos GC, De Moya M, Alam HB: Histone deacetylase inhibitors prevent apoptosis following lethal hemorrhagic shock in rodent kidney cells. Resuscitation 82: 105-109, 2011
28. Rangan GK, Wang Y, Tay YC, Harris DC: Cytokine gene expression in Adriamycin nephropathy: Effects of antioxidant nuclear factor kappaB inhibitors in established disease. Nephron 86: 482-490, 2000 (Pubitemid 32008842)
29. Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Grone HJ, Schlondorff D, Anders HJ: CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66: 2264-2278, 2004 (Pubitemid 41115289)
30. Wu H, Wang Y, Tay YC, Zheng G, Zhang C, Alexander SI, Harris DC: DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 67: 2178-2186, 2005 (Pubitemid 41623379)
31. Marshall CB, Krofft RD, Pippin JW, Shankland SJ: The CDK-inhibitor p21 is Pro-survival in adriamycin(R)-induced podocyte injury, in vitro and in vivo. Am J Physiol Renal Physiol 298: F1140-F1151, 2010
32. Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, Wiggins RC: Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 20: 1041-1052, 2009
33. van Beneden K, van Grunsven LA, Geers C, Pauwels M, Desmouliere A, Verbeelen D, Geerts A, van den Branden C: CRBP-I in the renal tubulointerstitial compartment of healthy rats and rats with renal fibrosis. Nephrol Dial Transplant 23: 3464-3471, 2008
34. Jeansson M, Bjorck K, Tenstad O, Haraldsson B: Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol 20: 114-122, 2009
35. Zheng Z, Schmidt-Ott KM, Chua S, Foster KA, Frankel RZ, Pavlidis P, Barasch J, D'Agati VD, Gharavi AG: A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc Natl Acad Sci U S A 102: 2502-2507, 2005 (Pubitemid 40279406)
36. Mundel P, Reiser J: Proteinuria: An enzymatic disease of the podocyte? Kidney Int 77: 571-580, 2010
37. Shankland SJ: The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147, 2006
38. Shiiki H, Sasaki Y, Nishino T, Kimura T, Kurioka H, Fujimoto S, Dohi K: Cell proliferation and apoptosis of the glomerular epithelial cells in rats with puromycin aminonucleoside nephrosis. Pathobiology 66: 221-229, 1998 (Pubitemid 28404335)
39. Griffin SV, Hiromura K, Pippin J, Petermann AT, Blonski MJ, Krofft R, Takahashi S, Kulkarni AB, Shankland SJ: Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol 165: 1175-1185, 2004 (Pubitemid 39297724)
40. Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010
41. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 19: 2282-2287, 2008
42. Kang YS, Li Y, Dai C, Kiss LP, Wu C, Liu Y: Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 78: 363-373, 2010
43. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: Past, present, and future. Kidney Int 72: 26-36, 2007 (Pubitemid 47014453)
44. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R: Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 21: 2069-2080, 2010
45. Johannessen CU: Mechanisms of action of valproate: A commentatory. Neurochem Int 37: 103-110, 2000
46. Chateauvieux S, Morceau F, Dicato M, Diederich M: Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010. doi: 10.1155/2010/479364
47. Bannister AJ, Kouzarides T: Regulation of chromatin by histone modifications. Cell Res 21: 381-395, 2011
48. Deman A, Ceyssens B, Pauwels M, Zhang J, Houte KV, Verbeelen D, van den Branden C: Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrol Dial Transplant 16: 147-150, 2001 (Pubitemid 32051489)
49. van den Branden C, Deman A, Ceyssens B, Pauwels M, Empsen C, Verbeelen D: Vitamin E protects renal antioxidant enzymes and attenuates glomerulosclerosis in adriamycin-treated rats. Nephron 91: 129-133, 2002 (Pubitemid 34522842)
50. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006 (Pubitemid 44197704)
51. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ: Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 75: 936-944, 2009